Massive Implants the Next Generation (MING)
Research type
Research Study
Full title
A randomised, single blind study assessing radiological outcomes for massive segmental femoral replacements using either porous collar or porous collar with HA or porous collar with HA and autologous stem cells
IRAS ID
234297
Contact name
Panos Gikas
Contact email
Sponsor organisation
Adler Ortho, iEthos Medical Ltd.
Duration of Study in the UK
2 years, 8 months, 26 days
Research summary
Aseptic loosening (caused by infection) of orthopaedic implants is a major problem in revision surgeries and in surgical treatments of bone cancer patients. Loosening of implants leads to failures, which require re-operations and limits patients’ quality of life. Finding ways to reduce aseptic loosening is important for improving longevity of implants and, as such, reduction of hospital re-admissions and re-operations.
Literature stipulates that by achieving osteointegration(structural connection between living bone and material surface) we can improve the longevity of implants. To enable osteointegration, we also need to reduce infections, which cause aseptic loosening. Published work suggests that coating implants with hydroxyapatite (a naturally occurring mineral) can reduce aseptic loosening.
Based on the work done to date we aim to compare 3 treatments:
- current standard treatment, which uses porous implants for femoral replacements,
-a porous implant coated with hydroxyapatite
- porous implant coated with hydroxyapatite and patients own cells.
The study will look at imaging of all 3 groups to determine, which intervention provides the best osteointegration with the least aseptic loosening.REC name
London - Westminster Research Ethics Committee
REC reference
18/LO/0274
Date of REC Opinion
1 May 2018
REC opinion
Further Information Favourable Opinion